Cantor Fitzgerald Weighs in on NeuroPace FY2026 Earnings

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of NeuroPace in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings per share of ($0.61) for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $17.00 target price on the stock. The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The company had revenue of $22.52 million for the quarter, compared to the consensus estimate of $21.85 million.

Other analysts have also recently issued research reports about the stock. HC Wainwright started coverage on shares of NeuroPace in a report on Wednesday, May 28th. They issued a "buy" rating and a $18.00 price objective on the stock. JPMorgan Chase & Co. increased their price objective on shares of NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a report on Wednesday, May 14th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, NeuroPace presently has an average rating of "Moderate Buy" and a consensus price target of $15.50.

NeuroPace Stock Performance

Shares of NPCE stock traded down $1.11 during trading hours on Tuesday, reaching $11.83. The stock had a trading volume of 351,232 shares, compared to its average volume of 166,361. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. NeuroPace has a twelve month low of $5.45 and a twelve month high of $18.98. The firm has a 50-day simple moving average of $12.89 and a 200-day simple moving average of $12.37. The firm has a market capitalization of $388.01 million, a PE ratio of -11.83 and a beta of 2.03.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Rhumbline Advisers boosted its holdings in shares of NeuroPace by 15.2% in the first quarter. Rhumbline Advisers now owns 17,227 shares of the company's stock worth $212,000 after buying an additional 2,267 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of NeuroPace by 54.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock worth $73,000 after buying an additional 2,279 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of NeuroPace in the fourth quarter worth about $29,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of NeuroPace by 7.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 39,237 shares of the company's stock worth $482,000 after buying an additional 2,700 shares during the period. Finally, GAMMA Investing LLC acquired a new position in shares of NeuroPace in the first quarter worth about $53,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at NeuroPace

In other news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the firm's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $15.85, for a total transaction of $2,664,955.60. Following the completion of the transaction, the insider now owns 3,238,199 shares in the company, valued at approximately $51,325,454.15. This trade represents a 4.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 22.20% of the stock is owned by corporate insiders.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.